Clinical Trials

NCT04858334 | RECRUITING | PHASE2
152 participants

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Study Type:
INTERVENTIONAL
Last Updated:
2026-05-29
Start Date:
2021-06-22
Completion:
2027-10-31
Conditions
  • Pancreatic Acinar Cell Carcinoma
  • Pancreatic Adenosquamous Carcinoma
  • Pancreatic Squamous Cell Carcinoma
  • Resectable Pancreatic Acinar Cell Carcinoma
  • Resectable Pancreatic Adenocarcinoma
  • Resectable Pancreatic Adenosquamous Carcinoma
  • Resectable Pancreatic Carcinoma
Interventions
  • DRUG
  • PROCEDURE
No Results Yet
NCT04739800 | ACTIVE_NOT_RECRUITING | PHASE2
120 participants

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Study Type:
INTERVENTIONAL
Last Updated:
2026-05-29
Start Date:
2021-06-10
Completion:
2023-01-26
Conditions
  • Fallopian Tube Mucinous Adenocarcinoma
  • Ovarian Seromucinous Carcinoma
  • Platinum-Refractory Fallopian Tube Carcinoma
  • Platinum-Refractory Ovarian Carcinoma
  • Platinum-Refractory Primary Peritoneal Carcinoma
  • Recurrent Fallopian Tube Clear Cell Adenocarcinoma
  • Recurrent Fallopian Tube Endometrioid Adenocarcinoma
  • Recurrent Fallopian Tube High Grade Serous Adenocarcinoma
  • Recurrent Fallopian Tube Mucinous Adenocarcinoma
  • Recurrent Fallopian Tube Transitional Cell Carcinoma
  • Recurrent Fallopian Tube Undifferentiated Carcinoma
  • Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma
  • Recurrent Ovarian Clear Cell Adenocarcinoma
  • Recurrent Ovarian Endometrioid Adenocarcinoma
  • Recurrent Ovarian High Grade Serous Adenocarcinoma
  • Recurrent Ovarian Low Grade Serous Adenocarcinoma
  • Recurrent Ovarian Mucinous Adenocarcinoma
  • Recurrent Ovarian Seromucinous Carcinoma
  • Recurrent Ovarian Transitional Cell Carcinoma
  • Recurrent Ovarian Undifferentiated Carcinoma
  • Recurrent Platinum-Resistant Fallopian Tube Carcinoma
  • Recurrent Platinum-Resistant Ovarian Carcinoma
  • Recurrent Platinum-Resistant Primary Peritoneal Carcinoma
  • Recurrent Primary Peritoneal Clear Cell Adenocarcinoma
  • Recurrent Primary Peritoneal Endometrioid Adenocarcinoma
  • Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma
  • Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma
  • Recurrent Primary Peritoneal Transitional Cell Carcinoma
  • Recurrent Primary Peritoneal Undifferentiated Carcinoma
  • Refractory Fallopian Tube Clear Cell Adenocarcinoma
  • Refractory Fallopian Tube Endometrioid Adenocarcinoma
  • Refractory Fallopian Tube High Grade Serous Adenocarcinoma
  • Refractory Fallopian Tube Mucinous Adenocarcinoma
  • Refractory Fallopian Tube Transitional Cell Carcinoma
  • Refractory Fallopian Tube Undifferentiated Carcinoma
  • Refractory Low Grade Fallopian Tube Serous Adenocarcinoma
  • Refractory Ovarian Clear Cell Adenocarcinoma
  • Refractory Ovarian Endometrioid Adenocarcinoma
  • Refractory Ovarian High Grade Serous Adenocarcinoma
  • Refractory Ovarian Low Grade Serous Adenocarcinoma
  • Refractory Ovarian Mucinous Adenocarcinoma
  • Refractory Ovarian Seromucinous Carcinoma
  • Refractory Ovarian Transitional Cell Carcinoma
  • Refractory Ovarian Undifferentiated Carcinoma
  • Refractory Primary Peritoneal Clear Cell Adenocarcinoma
  • Refractory Primary Peritoneal Endometrioid Adenocarcinoma
  • Refractory Primary Peritoneal High Grade Serous Adenocarcinoma
  • Refractory Primary Peritoneal Low Grade Serous Adenocarcinoma
  • Refractory Primary Peritoneal Transitional Cell Carcinoma
  • Refractory Primary Peritoneal Undifferentiated Carcinoma
Interventions
  • PROCEDURE
  • DRUG
  • BIOLOGICAL
NCT04739072 | RECRUITING
1000 participants

Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study

Study Type:
OBSERVATIONAL
Last Updated:
2026-05-29
Start Date:
2019-11-22
Completion:
2028-12-31
Conditions
  • Colorectal Adenocarcinoma
  • Stage I Colorectal Cancer AJCC v8
  • Stage II Colorectal Cancer AJCC v8
  • Stage IIA Colorectal Cancer AJCC v8
  • Stage IIB Colorectal Cancer AJCC v8
  • Stage IIC Colorectal Cancer AJCC v8
  • Stage III Colorectal Cancer AJCC v8
  • Stage IIIA Colorectal Cancer AJCC v8
  • Stage IIIB Colorectal Cancer AJCC v8
  • Stage IIIC Colorectal Cancer AJCC v8
  • Stage IV Colorectal Cancer AJCC v6
  • Stage IVA Colorectal Cancer AJCC v8
  • Stage IVB Colorectal Cancer AJCC v8
  • Stage IVC Colorectal Cancer AJCC v8
Interventions
  • PROCEDURE
  • OTHER
No Results Yet
NCT04586075 | RECRUITING
1000 participants

UW Undiagnosed Genetic Diseases Program

Study Type:
OBSERVATIONAL
Last Updated:
2026-05-29
Start Date:
2021-07-16
Completion:
2030-10-31
Conditions
  • Rare Diseases
  • Genetic Disease
  • Undiagnosed Disease
Interventions
  • DIAGNOSTIC_TEST
No Results Yet
NCT04579224 | ACTIVE_NOT_RECRUITING | PHASE3
184 participants

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2026-05-29
Start Date:
2021-06-28
Completion:
2030-08-15
Conditions
  • Metastatic Bladder Urothelial Carcinoma
  • Metastatic Urothelial Carcinoma
  • Refractory Bladder Urothelial Carcinoma
  • Refractory Urothelial Carcinoma
  • Stage IV Bladder Cancer AJCC v8
Interventions
  • PROCEDURE
  • DRUG
  • BIOLOGICAL
No Results Yet
NCT04532970 | COMPLETED | NA
651 participants

BAPS in Botswana: The Thotloetso Trial

Study Type:
INTERVENTIONAL
Last Updated:
2026-05-29
Start Date:
2021-05-06
Completion:
2025-12-01
Conditions
  • HIV Infections
  • Smoking Cessation
  • Smoking
Interventions
  • BEHAVIORAL
No Results Yet
Previous
Sorted by latest updates
Next
Showing 40 trials per page